No \u0161\u0101 gada 10.novembra Latvijas viet\u0113j\u0101 kapit\u0101la z\u0101\u013cu apg\u0101des uz\u0146\u0113muma AS \u201cRecipe Plus\u201d valdes priek\u0161s\u0113d\u0113t\u0101ja amat\u0101 darbu s\u0101cis Mantas Jurkus.<\/p>\n
L\u012bdz \u0161im uz\u0146\u0113muma vad\u012bt\u0101ja bija Vilma Fairclough, kura turpin\u0101s darbu k\u0101 AS \u201cSentor Farm aptiekas\u201d (\u201cM\u0113ness aptieka\u201d) valdes priek\u0161s\u0113d\u0113t\u0101ja un k\u013c\u016bs ar\u012b par AS \u201cRepharm\u201d valdes priek\u0161s\u0113d\u0113t\u0101ju.<\/p>\n
Augsti nov\u0113rt\u0113jot Vilmas Fairclough profesion\u0101lo ieguld\u012bjumu un vad\u012bbas pieredzi z\u0101\u013cu apg\u0101des un farmaceitisk\u0101s apr\u016bpes jom\u0101s, vi\u0146a turpm\u0101k nodro\u0161in\u0101s \u201cRepharm\u201d grupas uz\u0146\u0113mumu strat\u0113\u0123isko vad\u012bbu un att\u012bst\u012bbu, par priorit\u0101ti izvirzot kop\u012bgu m\u0113r\u0137i \u2013 uzlabot Latvijas pacientu pieredzi un apr\u016bpi vis\u0101 vesel\u012bbas apr\u016bpes cikl\u0101 un kvalitat\u012bvu pakalpojumu re\u0123ion\u0101lo pieejam\u012bbu.<\/p>\n
\u201c\u201cRepharm\u201d grupas m\u0113r\u0137is ir b\u016bt uzticamam un atbild\u012bgam vesel\u012bbas apr\u016bpes partnerim \u2013 gan valstij, gan katram Latvijas iedz\u012bvot\u0101jam un ar\u012b m\u016bsu sadarb\u012bbas partneriem. Stiprinot vad\u012bbas komandu ar jaunu, starptautisku vesel\u012bbas apr\u016bpes pieredzi guvu\u0161u \u201cRecipe Plus\u201d vad\u012bt\u0101ju, speram v\u0113l vienu soli \u0161aj\u0101 virzien\u0101. Esmu p\u0101rliecin\u0101ta, ka \u201cRecipe Plus\u201d Mantas Jurkus vad\u012bb\u0101 turpin\u0101s att\u012bst\u012bties, lai nodro\u0161in\u0101tu nep\u0101rtrauktu un stabilu z\u0101\u013cu apg\u0101di un pieejamu medic\u012bnas produktu portfeli ilgtermi\u0146\u0101. Vienlaikus str\u0101d\u0101sim pie t\u0101, lai v\u0113l augst\u0101ku kvalit\u0101ti, inov\u0101cijas un medic\u012bnisko apr\u016bpi sp\u0113jam nodro\u0161in\u0101t visos vesel\u012bbas apr\u016bpes posmos, kuros str\u0101d\u0101 \u201cRepharm\u201d grupas uz\u0146\u0113mumi,\u201d uzsver Vilma Fairclough.<\/p>\n
Mantas Jurkus ir pieredz\u0113jis vad\u012bt\u0101js ar vair\u0101k nek\u0101 20 gadu profesion\u0101lo pieredzi uz\u0146\u0113mumu att\u012bst\u012bb\u0101 un komandu vad\u012bb\u0101 da\u017e\u0101d\u0101s nozar\u0113s Baltijas un citu Eiropas valstu tirgos. Vi\u0146\u0161 ie\u0146\u0113mis vado\u0161us amatus uz\u0146\u0113mumos Henkel, IKI Lietuva, Maxima, Kesko Senukai, Daisena. Pirms pievieno\u0161an\u0101s \u201cRepharm\u201d grupai vi\u0146\u0161 str\u0101d\u0101ja uz\u0146\u0113mum\u0101 Kilo Health \u2013 vien\u0101 no visstrauj\u0101k augo\u0161ajiem Eiropas digit\u0101l\u0101s vesel\u012bbas uz\u0146\u0113mumiem, kur M.Jurkus k\u0101 starptautisk\u0101s tirdzniec\u012bbas vad\u012bt\u0101js bija atbild\u012bgs par darbu ASV un Eiropas tirgos.<\/p>\n
\u201cMan ir liels gods pievienoties \u201cRecipe Plus\u201d komandai. Mans galvenais uzdevums b\u016bs stiprin\u0101t m\u016bsu sp\u0113ju nodro\u0161in\u0101t iedz\u012bvot\u0101jiem dro\u0161u, \u0101tru un profesion\u0101lu z\u0101\u013cu pieejam\u012bbu un apg\u0101di, vienlaikus atbalstot vesel\u012bbas apr\u016bpes speci\u0101listus vis\u0101 Latvij\u0101. Kop\u0101 ar komandu turpin\u0101sim att\u012bst\u012bt pakalpojumus un m\u016bsu produktu portfeli, lai iedz\u012bvot\u0101jiem nepiecie\u0161am\u0101s z\u0101les un citi medic\u012bnas produkti vienm\u0113r b\u016btu pieejami aptiek\u0101s un \u0101rstniec\u012bbas iest\u0101d\u0113s,\u201d nor\u0101da Mantas Jurkus.<\/p>\n
AS \u201eRepharm\u201d, kas ir viet\u0113j\u0101 kapit\u0101la Latvijas uz\u0146\u0113mums, apvieno vesel\u012bbas apr\u016bp\u0113, farmaceitisko produktu mazumtirdzniec\u012bb\u0101 un apg\u0101d\u0113, laboratorisko izmekl\u0113jumu jom\u0101 str\u0101d\u0101jo\u0161us uz\u0146\u0113mumus. \u201cRepharm\u201d grupa apvieno t\u0101dus z\u012bmolus k\u0101 \u201cM\u0113ness aptieka\u201d, \u201cRecipe Plus\u201d, \u201cCentr\u0101l\u0101 laboratorija\u201d, \u201cVesel\u012bbas centru apvien\u012bba\u201d (VCA) un citus.<\/p>\n
2024.gad\u0101 vid\u0113jais darbinieku skaits uz\u0146\u0113mumu grup\u0101 2024. gad\u0101 bija 4450. \u201cRepharm\u201d ir viens no liel\u0101kajiem nodok\u013cu maks\u0101t\u0101jiem vesel\u012bbas apr\u016bpes nozar\u0113 Latvij\u0101, t\u0101 kop\u0113jais valsts kas\u0113 iemaks\u0101to nodok\u013cu apm\u0113rs par p\u0113rn sasniedza 68,6 miljonus eiro.<\/p>\n","protected":false},"excerpt":{"rendered":"No \u0161\u0101 gada 10.novembra Latvijas viet\u0113j\u0101 kapit\u0101la z\u0101\u013cu apg\u0101des uz\u0146\u0113muma AS \u201cRecipe Plus\u201d valdes priek\u0161s\u0113d\u0113t\u0101ja amat\u0101 darbu s\u0101cis…\n","protected":false},"author":2,"featured_media":46089,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[869,77,870,76,867,35,39,38,36,37,34,871,868,40,21],"class_list":{"0":"post-46088","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-bizness","8":"tag-biznesa-zinas","9":"tag-bizness","10":"tag-bizness-latvija","11":"tag-business","12":"tag-dienas-zinas","13":"tag-latvia","14":"tag-latvian","15":"tag-latviesu","16":"tag-latviesu-valoda","17":"tag-latviesuvaloda","18":"tag-latvija","19":"tag-latvijas-biznesa-zinas","20":"tag-latvijas-zinas","21":"tag-lv","22":"tag-zinas"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@lv\/115530864093960346","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/46088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/comments?post=46088"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/46088\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media\/46089"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media?parent=46088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/categories?post=46088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/tags?post=46088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}